What is Tofacitinib Citrate API?
Tofacitinib citrate is the active pharmaceutical ingredient (API) used in the drug Xeljanz, a Janus kinase (JAK) inhibitor. It is prescribed to treat certain autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1].
What are the Quality Standards for Tofacitinib Citrate API?
The specification for Tofacitinib Citrate API refers to the set of quality standards and tests that the API must meet to ensure its purity, potency, and safety. These specifications are typically detailed in regulatory filings and pharmacopeial monographs. Key aspects of an API specification often include:
* Identification: Tests to confirm the identity of the API, ensuring it is indeed tofacitinib citrate.
* Assay: Determination of the API's strength or potency, typically expressed as a percentage.
* Purity: Limits for impurities, including related substances (degradation products or synthesis byproducts) and residual solvents.
* Water Content: Measurement of moisture content, which can affect stability.
* Heavy Metals: Limits for potentially toxic heavy metal contaminants.
* Microbial Limits: Tests to ensure the API is free from unacceptable levels of microorganisms.
* Physical Characteristics: Properties such as appearance, solubility, and particle size distribution [2].
These specifications are critical for ensuring that each batch of the API is consistent and suitable for pharmaceutical manufacturing.
Who Manufactures Tofacitinib Citrate API?
The primary manufacturer of Tofacitinib Citrate API is Pfizer Inc., the developer of Xeljanz [1]. However, as patents expire, other manufacturers may produce generic versions of the API.
When Does the Patent for Tofacitinib Citrate Expire?
The patent landscape for tofacitinib citrate can be complex, involving multiple patents covering the compound, its synthesis, and its use. Information on patent expiry dates can be found through resources like DrugPatentWatch.com [3].
What is the Difference Between Tofacitinib and Tofacitinib Citrate?
Tofacitinib is the base drug molecule. Tofacitinib citrate is the salt form of tofacitinib, where it is combined with citric acid. The citrate salt form is often used in pharmaceutical formulations because it can improve properties such as solubility, stability, and bioavailability of the API [1].
What are the Clinical Uses of Tofacitinib Citrate?
Tofacitinib citrate is approved for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and moderate to severe active ulcerative colitis in adults who have had an inadequate response or intolerance to other therapies [1].
What are the Potential Risks or Side Effects Associated with Tofacitinib Citrate?
Patients taking tofacitinib citrate may experience serious side effects, including increased risk of serious infections, blood clots, heart attack, stroke, and certain cancers. It is important for patients to discuss these risks with their healthcare provider [1].